Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB

Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB

The mortality rate of patients who develop sepsis-related cardiac dysfunction is high. Many disease conditions (e.g., diabetes) increase the susceptibility to infections and subsequently sepsis. Activation of the NF-κB pathway plays a crucial role in the pathophysiology of sepsis-associated cardiac...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser: Sura Al Zoubi, Jianmin Chen, Catherine Murphy, Lukas Martin, Fausto Chiazza, Debora Collotta, Muhammad M. Yaqoob, Massimo Collino, Christoph Thiemermann
Format: Artikel
Sprache:English
Veröffentlicht: Frontiers Media S.A. 2018-12-01
Schriftenreihe:Frontiers in Immunology
Schlagworte:
sepsis
septic cardiomyopathy
NF-κB
IKK-16
DPP-4
linagliptin
Online Zugang:https://www.frontiersin.org/article/10.3389/fimmu.2018.02996/full

Online

https://www.frontiersin.org/article/10.3389/fimmu.2018.02996/full

Ähnliche Einträge